Other EGFR-TKI resistant mechanisms, such as EMT, PTEN loss, and activation of IGF-1R, should be further investigated to determine their influence on PD-L1 expression on EGFR-TKIs resistant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.